Clinical Trials Logo

Clinical Trial Summary

Acutely decompensated heart failure (ADHF) is highly prevalent and has a high (financial) burden on the health care system. Treatment often consists of the administration of IV decongestive agents. Adequate dosing is difficult due to varying diuretic resistance and inadequate parameters to evaluate the response. Urine sodium is a promising biomarker to evaluate the diuretic response. It is hypothesized that a tailored, urine sodium guided diuretic algorithm will result in faster and more complete decongestion and therefore lead to better survival (in terms of mortality and heart failure events) while being non-inferior in terms of safety (mainly regression of kidney function).


Clinical Trial Description

Rationale: Acutely decompensated heart failure is a highly prevalent diagnosis with a high burden on resources and a high risk of mortality and re-hospitalization. The prescription of diuretics to relieve congestion has been the cornerstone of treatment for years, but evidence about diuretic response and adequate dosing is still lacking. Inadequate diuretic response (and insufficient decongestion) has a negative influence on outcome but is often not timely addressed. Urinary sodium (Ur-Na) is a promising biomarker in the prediction of diuretic response to the prescribed dose. It is hypothesized that an Ur-Na based, intensified algorithm can help tailor diuretics in an individual way, but sufficient evidence to support its implementation is lacking. Objective: Investigate if a tailored diuretic algorithm based on Ur-Na has a positive effect on a primary endpoint of reduction in a combined endpoint of death, heart failure events and change in the Kansas City questionnaire total symptom score (KCCQ-TSS) versus standard clinical care in patients hospitalized with AHF, without imposing safety concerns (e.g. worsening renal function). Study design: Prospective, Single-Blinded, Randomized, Blinded-endpoint trial Study population: Patients admitted with acutely decompensated heart failure (diagnosed according to the 2021 ESC (European Society of Cardiology) guidelines) who are 18 year or older. Intervention: Arm I: Tailored, Ur-Na based, intensified diuretic strategy; Arm II: Usual care Main study parameters/endpoints: Hierarchical composite endpoint of all-cause death, heart failure events and a 4-point or greater difference in Kansas City questionnaire total symptom score (KCCQ-TSS); assessed using a win-ratio approach. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT06092437
Study type Interventional
Source Zuyderland Medisch Centrum
Contact Sandra van Wijk, MD, PhD
Phone 088 - 459 9701
Email s.vanwijk@zuyderland.nl
Status Recruiting
Phase N/A
Start date February 27, 2023
Completion date February 27, 2026

See also
  Status Clinical Trial Phase
Not yet recruiting NCT04080388 - How to Prevent Heart Failure Readmission by Using Lung Impedance Device (HOPE-HF Study) Phase 3
Recruiting NCT04751838 - Development and Validation of a Simple-to-use Nomogram for Predicting In-hospital Mortality in Acute Heart Failure Patients Undergoing Continuous Renal Replacement Therapy
Active, not recruiting NCT04618601 - Diuretic and Natriuretic Effect of High-dose Spironolactone in Patients With Acute Heart Failure Phase 4
Recruiting NCT06142474 - SGLT2 Inhibitors in Patients With ADHF During Ventilator Weaning Phase 3
Active, not recruiting NCT05603247 - The SWISSHEART Failure Network (SHFN)
Recruiting NCT03169803 - Cardiac Output Autonomic Stimulation Therapy for Acute Heart Failure (COAST-AHF) N/A
Not yet recruiting NCT06273397 - Acetazolamide or Metolazone in Acute Heart Failure N/A
Recruiting NCT03542123 - Cardiac Output Autonomic Stimulation Therapy for Heart Failure - Hemodynamic Effects N/A
Completed NCT04878263 - Evaluation and Support Care Process Within the Care Pathway of Heart Failure Patients N/A
Not yet recruiting NCT06442280 - SGLT-2 Inhibitor and High-Dose Furosemide Plus Small-Volume Hypertonic Saline Solution in Acute HF Phase 4
Completed NCT04281849 - Balance, Aerobic Capacity, Mobility and Strength in Patients Hospitalized for Heart Failure (BAMS-HF) Program N/A
Not yet recruiting NCT04403659 - Telemonitoring of Patients Admitted in Hospital at Home With Acute Decompensated Heart Failure - Pilot Study N/A
Terminated NCT03574857 - Prospective Comparison of Metolazone Versus Chlorothiazide for Acute Decompensated Heart Failure With Diuretic Resistance Phase 4
Completed NCT03136198 - B-lines Lung Ultrasound Guided ED Management of Acute Heart Failure Pilot Trial Phase 2
Terminated NCT03746002 - Diuretic Effect of Metolazone Pre-dosing Versus Concurrent Dosing Phase 4
Active, not recruiting NCT03513653 - Strain for Risk Assessment and Therapeutic Strategies in Patients With Acute Heart Failure (STRATS-AHF) Registry
Recruiting NCT05746923 - Lesser Poland Cracovian Heart Failure Registry
Recruiting NCT06414928 - Prognostic Model Heart Failure
Completed NCT04606927 - Pragmatic Urinary Sodium-based Treatment algoritHm in Acute Heart Failure N/A
Completed NCT03200860 - Effects of Empagliflozin on Clinical Outcomes in Patients With Acute Decompensated Heart Failure Phase 2